Sub Banner Image

Novartis Sees Hope In Reducing Lifelong Treatment Burden For Autoimmune Blood Disorder

Market Impact

Vandana Singh

·

August 12, 2025

·

Benzinga

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 immune thrombocytopenia trial.

read more

More from

Benzinga

More

Market Impact

Articles

Trending News

Enjoy premium content in your inbox.

You're in! Check your email to learn more.
Oops! Something went wrong while submitting the form.